Breaking News

Cidara Therapeutics Receives $11M Milestone for European Approval of REZZAYO

Marks a significant milestone for patients who are in need of new treatment options for invasive candidiasis.

Author Image

By: Charlie Sternberg

Associate Editor

Cidara Therapeutics Inc., a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies, has received an $11.14 million milestone payment from Mundipharma following the European approval of REZZAYO (rezafungin acetate), a novel, once-weekly echinocandin antifungal approved for the treatment of invasive candidiasis in adults.   This approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters